Research programme: immunotherapies and vaccines - Heat Biologics

Drug Profile

Research programme: immunotherapies and vaccines - Heat Biologics

Alternative Names: Anti-TLIA - Heat Biologics; Anti-TNFRSF25 - Heat Biologics; Fc-OX40L; HS 310 - Heat Biologics; HS-120; HS-210; HS-310; HS-HCV; HS-HIV; HS-HIV/SIV; HS-HIV1; HS-O1; HS-P1; IN-A1; Inhibicor; Medicor

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heat Biologics
  • Developer Heat Biologics; OncoSec Medical
  • Class AIDS vaccines; Antibodies; Cancer vaccines; Cell therapies; Heat shock proteins; Immunoglobulin fusion proteins; Tumour cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants; Tumour necrosis factor ligand superfamily member 15 inhibitors; Tumour necrosis factor member 25 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours
  • Suspended Hepatitis C
  • Discontinued Asthma; Autoimmune disorders; HIV-1 infections; Transplant rejection

Most Recent Events

  • 14 Nov 2016 Pharmacodynamics data from a preclinical trial in Cancer released by Heat Biologics
  • 25 Apr 2016 Discontinued - Preclinical for HIV-1 infections in USA (Parenteral) (Heat Biologics' pipeline April- 2016)
  • 18 Apr 2016 Preclinical trials in Solid tumours in USA (Parenteral) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top